Skip to main content
Premium Trial:

Request an Annual Quote

OGT Receives ISO/IEC 27001 Accreditation


By Justin Petrone

Oxford Gene Technology said this week that it has achieved compliance with ISO/IEC 27001:2005, an international information security management standard published by the International Organization for Standardization and the International Electrotechnical Commission.

ISO/IEC 27001 requires that management examines its information security risks; implements a suite of information security controls to mitigate those risks; and adopts overarching management process to ensure the controls meet its security needs on an ongoing basis.

OGT said all of its data generation and security procedures were recently certified to meet ISO/IEC 27001 by the British Standards Institution. The certification extends to the management of OGT's CytoSure and Genefficiency services, biomarker discovery solutions, and the development of CytoSure Interpret Software, it added.

CEO Mike Evans said in a statement that the certification "demonstrates [OGT's] ongoing commitment to information security and confidentiality" and its ability to "protect the integrity and confidentiality of all information and data."

OGT achieved ISO 9001:2008 accreditation earlier this year (BAN 6/14/2010).

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.